<?xml version="1.0" encoding="UTF-8"?>
<p>Secondly, research related to the platform for an immunological response to viral infection and vaccine development (Sub-Cluster 1-2) was comprised of 38 projects worth 146,167,160 USD. The University of North Carolina Chapel Hill in the US is projected to have spent 24 million USD on its “Systems immunogenetics of biodefense and emerging pathogens in the collaborative cross” by the time the 10 year project wraps up in 2022. The New York Blood Center committed to spending 4.5 million USD on a vaccine project titled “Structure-based design of coronavirus subunit vaccines” between 2018 and 2023. Meanwhile, The National Institute of Infectious Diseases of Japan finished a vaccine project costing 144,300 USD between 2016 and 2019 (see 
 <xref rid="healthcare-08-00204-t003" ref-type="table">Table 3</xref>).
</p>
